Results 21 to 30 of about 510,697 (405)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis

Arthritis & Rheumatology, 2021
To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19 subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER‐2 trial.
I. McInnes, P. Rahman, A. Gottlieb, E. Hsia, A. Kollmeier, Xie L. Xu, Yusang Jiang, S. Sheng, M. Shawi, S. Chakravarty, D. van der Heijde, P. Mease   +11 more
semanticscholar   +1 more source

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

Annals of the Rheumatic Diseases, 2020
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the EULAR standardised operating procedures, a systematic literature review was ...
L. Gossec, X. Baraliakos, A. Kerschbaumer, M. D. de Wit, I. McInnes, M. Dougados, J. Primdahl, D. McGonagle, D. Aletaha, A. Bălănescu, P. Bálint, H. Bertheussen, W. Boehncke, G. Burmester, J. Cañete, N. Damjanov, T. Kragstrup, T. Kvien, R. Landewé, R. Lories, H. Marzo-Ortega, D. Poddubnyy, Santiago Rodrigues Manica, G. Schett, D. Veale, F. E. Van den Bosch, D. M. van der Heijde, J. Smolen   +27 more
semanticscholar   +1 more source

Tissue‐Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis

Arthritis & Rheumatology, 2021
To compare immune cell phenotype and function in psoriatic arthritis (PsA) versus psoriasis in order to better understand the pathogenesis of PsA.
E. Leijten, T. V. van Kempen, M. O. Olde Nordkamp, J. Pouw, N. J. Kleinrensink, N. Vincken, J. Mertens, D. Balak, F. Verhagen, S. Hartgring, E. Lubberts, J. Tekstra, A. Pandit, T. Radstake, M. Boes   +14 more
semanticscholar   +1 more source

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

BMJ Open, 2022
Introduction Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with psoriasis progress to PsA.
Joseph F Merola, Lihi Eder, Proton Rahman, Soumya D Chakravarty, Jose U Scher, Alexis Ogdie, Rebecca B Blank, Vincent Piguet, C T Ritchlin, Jonathan Samuels, Kun Qian, Wayne Gulliver, Ralf G Thiele, Rebecca H Haberman, Rochelle Castillo, Cinty Gong, Andrea L Neimann, Katrina A MacFarlane, Sydney Catron, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Francisco Tausk, Jensen Yeung   +23 more
doaj   +1 more source

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

Arthritis & Rheumatology, 2022
To assess the long‐term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA).
L. Coates, I. McInnes, J. Merola, R. Warren, A. Kavanaugh, A. Gottlieb, L. Gossec, D. Assudani, R. Bajracharya, J. Coarse, B. Ink, C. Ritchlin   +11 more
semanticscholar   +1 more source

CLINICAL PRESENTATION OF PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS IN EARLY STAGES - SIMILARITIES AND DIFFERENCES IN DIAGNOSIS

Arta Medica, 2023
Introduction. Psoriatic arthritis, as well as rheumatoid arthritis are presented by a heterogeneity of clinical manifestations in the early stages. Objective. Improvement of early diagnosis of psoriatic arthritis based on clinical data, laboratory and
Eugeniu Russu, Liliana Groppa, Lia Chișlari, Alesea Nistor, Lucia Dutca, Liudmila Gonța   +5 more
doaj   +1 more source

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review

Therapeutic Advances in Musculoskeletal Disease, 2021
Psoriatic arthritis (PsA) is associated with a higher burden of cardiometabolic disorders, such as hypertension, dyslipidemia, diabetes, obesity, and cardiovascular disease (CVD), compared with the general population.
P. Karmacharya, A. Ogdie, L. Eder
semanticscholar   +1 more source

Psoriatic arthritis [PDF]

Polish Journal of Radiology, 2013
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease which develops in patients with psoriasis. It is characteristic that the rheumatoid factor in serum is absent. Etiology of the disease is still unclear but a number of genetic associations have been identified.
Sankowski, Artur Jacek, Łebkowska, Urszula Maria, Ćwikła, Jarosław, Walecka, Irena, Walecki, Jerzy   +4 more
openaire   +3 more sources

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Therapeutic Advances in Musculoskeletal Disease, 2021
Background: Involvement of the axial skeleton (sacroiliac joints and spine) is a relatively frequent manifestation associated with psoriatic skin disease, mostly along with involvement of peripheral musculoskeletal structures (peripheral arthritis ...
D. Poddubnyy, X. Baraliakos, F. E. Van den Bosch, J. Braun, L. Coates, V. Chandran, T. Diekhoff, F. V. van Gaalen, L. Gensler, N. Goel, A. Gottlieb, D. van der Heijde, P. Helliwell, K. Hermann, D. Jadon, R. Lambert, W. Maksymowych, P. Mease, P. Nash, F. Proft, M. Protopopov, J. Sieper, M. Torgutalp, D. Gladman   +23 more
semanticscholar   +1 more source

Psoriatic arthritis [PDF]

Expert Opinion on Investigational Drugs, 2000
Psoriatic arthritis occurs in 5 - 42% of patients with psoriasis. It is an inflammatory arthritis distinct from rheumatoid, being usually sero-negative, asymmetrical and often affecting the spine, sacro-iliac and distal interphalangeal joints. It runs a very variable course, from a mild non-destructive disease to a severe rapidly progressive erosive ...
D D, Gladman, J, Brockbank
openaire   +4 more sources